H.C. Wainwright raised the firm’s price target on Harpoon Therapeutics to $12 from $7.50 and keeps a Buy rating on the shares after the company reported additional clinical data from the ongoing Phase 1 study evaluating HPN217 for the treatment of multiple myeloma. The firm says the optimal response rate and safety profile support 12mg as the recommended Phase 2 dose.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HARP:
- Harpoon Therapeutics presents HPN217 Phase 1 data in RRMM
- Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
- Harpoon Therapeutics files to sell 25.75M shares of common stock for holders
- Harpoon Therapeutics initiated with an Outperform at TD Cowen
- Biotech Alert: Searches spiking for these stocks today
